Who We Are

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

Our Pipeline

Our lead product, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01’s novel mechanism of action is designed to reestablish tear film homeostasis by activating natural tear film production.

Latest News

9/1/2021

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8/5/2021

Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights